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Introduction: SCLC accounts for approximately 250,000
deaths worldwide each year. Acquisition of adequate tumor
biopsy samples is challenging, and liquid biopsies present
an alternative option for patient stratification and response
monitoring.
Methods: We applied whole genome next-generation
sequencing to circulating free DNA (cfDNA) from 39 pa-
tients with limited-stage (LS) SCLC and 30 patients with
extensive-stage SCLC to establish genome-wide copy
number aberrations and also performed targeted mutation
analysis of 110 SCLC associated genes. Quantitative met-
rics were calculated for copy number aberrations,
including percent genome amplified (PGA [the percentage
of genomic regions amplified]), Z-score (a measure of
standard deviation), and Moran’s I (a measure of spatial
autocorrelation). In addition CellSearch, an epitope-
dependent enrichment platform, was used to enumerate
circulating tumor cells (CTCs) from a parallel blood
sample.
Results: Genome-wide and targeted cfDNA sequencing data
identified tumor-related changes in 94% of patients with LS
SCLC and 100% of patients with extensive-stage SCLC.
Parallel analysis of CTCs based on at least 1 CTC/7.5 mL of
blood increased tumor detection frequencies to 95% for LS
SCLC. Both CTC counts and cfDNA readouts correlated with
disease stage and overall survival.Journal of Thoracic Oncology Vol. 15 No. 2: 216-230Conclusions:We demonstrate that a simple cfDNA genome-
wide copy number approach provides an effective means of
monitoring patients through treatment and show that tar-
geted cfDNA sequencing identifies potential therapeutic
targets in more than 50% of patients. We are now incor-
porating this approach into additional studies and trials of
targeted therapies.
 2019 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
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Introduction
SCLC is an aggressive neuroendocrine tumor ac-
counting for 10% to 15% of the 1.8 million lung cancers
diagnosed worldwide annually. SCLC is strongly associ-
ated with tobacco smoke carcinogen exposure1 and
characterized by high growth rate and early metastatic
spread. Most patients with SCLC present with extensive-
stage (ES) SCLC with distant metastases and median
overall survival (OS) of less than 1 year despite treat-
ment with platinum-based chemotherapy.2 Patients with
limited-stage (LS) SCLC, which is localized and encom-
passable within a single radiotherapy field, have a me-
dian survival of 18 months. Durable responses to
treatment (>5 years) are seen in approximately 20% to
30% of patients with LS SCLC but only less than 2% of
patients with ES SCLC.3
Genomic analysis of SCLC tumors have identified
extensive copy number alterations (CNAs) and high
mutation rates.4,5 There is almost universal inactivation
and prevalent loss of the tumor suppressors tumor
protein p53 gene (TP53) and retinoblastoma 1 gene
(RB1) and frequent amplification of transcriptional
regulators (SRY-box transcription factor 2 gene [SOX2],
nuclear factor I B gene [NFIB], v-myc avian myelocy-
tomatosis viral oncogene lung carcinoma derived ho-
molog gene [MYCL1], v-myc avian myelocytomatosis
viral oncogene neuroblastoma derived homolog gene
[MYCN], and v-myc avian myelocytomatosis viral onco-
gene homolog gene [MYC]), with recurrent mutations of
Notch and histone acetyltransferase genes (CREB
binding protein gene [CREBBP] and E1A binding protein
p300 gene [EP300]).4-6 Tumor biopsies, and particularly
serial biopsies, in SCLC are a significant challenge,7,8
hampering our understanding of the rapidly evolving
biology of SCLC and development of targeted therapies.
Surgical resection of SCLC is rare, yet by necessity, most
genomic studies have been performed on resected tu-
mors4,9 and hence may be unrepresentative of most
patients. Fine-needle aspirates or biopsy samples are
often of poor quality and/or quantity or unavailable for
research. Nevertheless, recent advances that have star-
ted to deliver new therapy candidates including
exploitation of Notch ligand, delta-like ligand 3 to
deliver a cytotoxic payload,10 synthetic lethal strategies
targeting cell cycle regulation, oncogene-driven repli-
cation stress and DNA damage repair (DDR) responses
are under evaluation in early clinical trials.11 Positiveresults are also emerging from trials of immune
checkpoint targeting, including the phase III trial
IMPower133, which combines immune checkpoint in-
hibition with cytotoxic chemotherapy which has shown
significantly longer OS and progression-free survival in
the treatment arm.12,13 Over the past decade, it has
been established that a “liquid biopsy” sample from
peripheral blood can facilitate analysis of tumor DNA
present in either circulating tumor cells (CTCs)8 or
circulating free DNA (cfDNA).7,14 Liquid biopsy data
often correlates with the genomic variants in matched
tumor tissue and can extend the genomic profile
detected.8,15,16 Liquid biopsies overcome many limita-
tions associated with tissue sampling and can be
scheduled before, during, and after therapy, enabling
assessment of tumor burden, treatment response, and
genetic changes associated with drug resistance.17
A number of studies, including our own, have shown
that CTC numbers are higher in SCLC than in other
cancer types and constitute an independent prognostic
biomarker for OS.18 We also demonstrated that a CNA
signature, measured in single CTCs from pretreatment
blood samples, predicts duration of response to
chemotherapy.8 Despite widespread development of
cfDNA molecular readouts for diagnostic, predictive,
prognostic, and minimal residual disease detection
across many cancer types,14,16,19 there have been few
studies of ctDNA in SCLC.7,20-23 For optimal use in SCLC
clinical trials and eventual routine clinical imple-
mentation, a cfDNA-based assay should (1) quantify
circulating tumor DNA (ctDNA) to monitor the presence
and extent of disease and (2) identify ctDNA alterations
that inform therapeutic decision making. Prior studies
have demonstrated that SCLC ctDNA can be identified
and profiled by detecting either a single gene of inter-
est, TP53,7 or a panel of SCLC-associated genes,20,21 as
well as for patient monitoring using a panel of 430
genes.22
Here we describe a flexible and sensitive workflow
for ctDNA detection based on next-generation
sequencing (NGS) of cfDNA that was developed for
use in SCLC clinical trials (Fig. 1A). After the generation
of a single whole genome NGS library from each SCLC
cfDNA sample, an initial aliquot is used for the detec-
tion of CNA by means of shallow whole genome
sequencing, and a second aliquot is used for target
enrichment of a panel of 110 genes recurrently
mutated in SCLC. We applied this simple workflow to a
pilot study of 69 samples from patients with SCLC (39
with LS SCLC and 30 with ES SCLC) and detected tumor
associated-changes in cfDNA, including both CNA and
putative cancer driver mutations in 94% of patients
with LS SCLC and 100% of patients with ES SCLC.
Additionally, for six patients, we demonstrate that
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Sex, n (%)
Male 15 (38) 16 (53)
Female 24 (62) 14 (47)
Performance status (PS), n (%)
PS 0 12 (31) 3 (10)
PS 1 19 (49) 15 (50)
PS 2 5 (13) 8 (27)
PS 3 1 (3) 3 (10)
PS 4 1 (3) 0 (0)
PS not recorded 1 (3) 1 (3)
CTC = 0 8 (21) 4 (13)
CTC ≤ 2 6 (15) 3 (10)
CTC > 2 ≤ 15 8 (27)
CTC > 15 ≤ 50 4 (10) 5 (17)
CTC > 50 2 (5) 9 (30)
CTC Not Recorded 13 (33) 1 (3)
CTC Not recorded 14 978
Overall Survival, in days
524 212
Site of metastases, n (%)
Metastatic sites 0 38 (97) 0 (0)
Metastatic sites 1 0 (0) 10 (33)
Metastatic sites 2 1 (3) 12 (40)
Metastatic sites 3 0 (0) 6 (20)
Metastatic sites 4 0 (0) 2 (7)
Range 53 – 83 49 – 81
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15 ± 27 978 ± 3103
2 11
0 – 116 0 – 15,352
4 – 1576 89 – 546
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6 (15)
Figure 1. (A) Workflow illustrating genomic analysis of SCLC whole blood. Blood samples for circulating free DNA (cfDNA)
analysis was collected in Cell-Free DNA blood collection tubes (Streck), CellSave, Becton Dickinson (BD) Vacutainer K2EDTA,
or BD Vacutainer Heparin and for germline DNA analysis in the BD Vacutainer K2EDTA vacutainer. (B) Demographics of 69
patients with SCLC included in this study. LS, limited-stage; ES, extensive-stage; CTC, circulating tumor cell.
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means of disease monitoring.Materials and Methods
Collection of Blood Samples from NCCs and
Patients
Blood samples were collected in either Cell-Free DNA
BCT tubes (Streck, Omaha, NE), CellSave, BD Vacutainer
K2 ethylenediaminetetraacetic acid (K2EDTA), or BD
Vacutainer heparin for cfDNA analysis along with a BD
Vacutainer K2EDTA vacutainer (BD Biosciences, Heidel-
berg, Germany) for germline DNA analysis. All samples
were collected either from volunteers without cancer,referred to as non-cancer controls (NNCs) (i.e., persons
who do not currently have cancer or were not being
treated for it, University of Manchester ethics committee
approval no. 2017-2761-4606), or from patients with
SCLC (ChemoRes and CONVERT Trials) after receipt of
informed consent in compliance with the Declaration of
Helsinki and Good Clinical Practice after approval from
the internal review and the ethics boards of the Christie
Hospital National Health Service Trust (research ethics
committee [REC] approval no. 07/H1014/96). The Che-
moRes trial was reviewed in the United Kingdom by the
National Research Ethics Service Committee North
West–Greater Manchester West, which granted ethics
approval for the study on February 26, 2008 (REC
February 2020 Profiling cfDNA in SCLC 219reference no. 07/H1014/96). The CONVERT trial was
reviewed in the UK by the National Research Ethics
Service Committee North West–Greater Manchester
Central, which granted ethics approval for the study on
December 21, 2007 (REC reference no. 07/H1008/229).
Samples were collected for this study from a total of 32
NCCs and 69 patients with SCLC (Fig. 1B). We have
examined whether the inclusion of heparin plasma
samples for cfDNA affects the overall readouts, and this
is shown in Supplementary Fig. 1.
Preparation of CNA Control Nucleosomal DNA
For nucleosomal fragmentation we applied the EZ
Nucleosomal DNA Prep Kit (Zymo Research, Orange, CA)
to the SCLC cell line H446 and peripheral blood mono-
nuclear cells (PBMCs). Serial dilutions were created to
give H446 DNA as 100%, 20%, 10%, 5%, 1%, and 0%
against a background of PBMC DNA (Supplementary
Fig. 2A and B). Each diluted sample was subjected to
whole genome NGS using inputs of 20 ng and 5 ng to
approximate the range of input cfDNA seen in patient
samples. All NGS samples were sequenced at low depth
to evaluate CNAs.
Circulating Cell-Free DNA and Germline DNA
Extraction
Blood sample processing, extraction of cfDNA and
germline DNA, and subsequent DNA quantification were
performed as previously described.16 In brief, cfDNA was
isolated by using the QIAmp Circulating Nucleic Acid Kit
(Qiagen) according to the manufacturer’s instructions
and/or the QIAsymphony with the Circulating DNA Kit
(Qiagen). Germline DNA was isolated from EDTA whole
blood by using the QIAmp Blood Mini Kit (Qiagen) ac-
cording to the manufacturer’s instructions and sheared
to 200 to 300 base pairs on the Bioruptor Pico
(Diagenode). Sheared germline DNA and cfDNA yields
were quantified by using the TaqMan RNase P Detection
Reagents Kit (Life Technologies).
NGS Library Preparation and Whole Genome
Sequencing
Whole genome cfDNA and germline DNA libraries
from the patients and from NCCs were carried out as
previously described.16 In brief, whole genome libraries
were generated from 2 ng to 25 ng of cfDNA or from
25ng of sheared germline DNA by using Accel-NGS 2S
DNA Library Kits for the Illumina platform (Swift Bio-
sciences) according to the manufacturer’s instructions
with the following modifications. Library amplification
and indexing was carried out with KAPA HiFi HotStart
Polymerase Chain Reaction (PCR) Kits (Kapa Bio-
systems) and NEBNext Index Primers for Illumina (NewEngland Biolabs). Paired-end sequencing (300 cycles)
was performed on the Illumina MiSeq benchtop
sequencer (Illumina, San Diego, CA) by using the MiSeq
Reagent Kit v2 (Illumina).
Targeted NGS Analysis
Targeted NGS of 110 SCLC associated genes
(Supplementary Table 1) for whole genome libraries
from cfDNA and corresponding germline DNA were
carried out by using Agilent SureSelectXT essentially as
described previously.16 In brief, 1mg of each whole
genome indexed library was pooled (up to 6mg or six
libraries) as input for custom capture (110-gene panel)
on SureSelectXT Reagent Kits (Agilent) according to the
manufacturer’s instructions. Captured libraries were
amplified by using KAPA HiFi HotStart PCR Kits and
quantified by using the KAPA Library Quantification
qPCR kit (Roche). Libraries were paired-end sequenced
on an Illumina NextSeq 500, 2 150 base pairs High
Output V2 Kit (Illumina).Somatic Mutation Detection from Targeted
Resequencing Data
Somatic mutations and indels were called as was
previously described.16 FASTQ files were generated
from the sequencer’s output by using Illumina
bcl2fastq2 software (version 2.17.1.14, Illumina) with
the default chastity filter to select sequence reads for
subsequent analysis. All sequencing reads were aligned
to the human genome reference sequence (GRCh37) by
using the Burrows-Wheeler aligner (version 0.7.12)
maximal exact matches algorithm. Picard tools (version
2.1.0) were used to mark and/or remove PCR dupli-
cates and to calculate sequencing metrics. Somatic
point mutations were called by using both MuTect
(version 1) and the commercial software, Biomedical
Genomics Workbench (BGW) (version .5.0) (Qiagen), by
comparing plasma cfDNA with germline control DNA.
Somatic InDels were called by using both VarScan and
BGW. Mutations called by two independent pipelines
(MuTectþBGW or VarScanþBGW) were classed as
high-confidence and kept. Only cfDNA variants with a
variant allele fraction (VAF) at least three times that of
the matching germline DNA VAF were called to filter
out likely clonal haematopoiesis and germline variants
from the cfDNA signal.24
The quality control measures were as follows. First,
all samples were considered for analysis if they had a
minimum coverage of 100 for cfDNA and the corre-
sponding germline DNA. Second, if the error rate as
measured by Qualimap was above 1.5% for cfDNA and
germline DNA, these samples were rejected from further
analysis (Supplementary Table 2).
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CNA analysis was performed by using HMMCopy af-
ter size selection of cfDNA fragments; down-sampling of
uniquely mapped sequencing reads to 1 million and
removal of noisy bins. Further CNA scores—PGA, z score,
and Moran’s I (MI)—were calculated. The
Supplementary Appendix provides detailed information
of the bioinformatic analysis for CNA and score
calculation.
Statistical Analyses
For the survival analysis, the continuous variables in
the data set were not normally distributed, nor could
they be normalized by using transformation. The data
have been categorized by using the maximally selected
rank statistic to select the optimal cutpoint. None of the
models violated the proportionality of hazard assump-
tion. Selection of the predictors for the multivariate
model was done by using elastic net penalized regres-
sion with the significant univariate variables as input.
Multivariate imputation by chained equations with pre-
dictive mean matching was used to handle the missing
data. The hyperparameters of the elastic net were
selected by using 10-fold cross validation. Selected pre-
dictors that are correlated have been excluded on the
basis of their variance inflation factor.
Associations between disease stage and mutation
profiles, CTC number, CNA metrics, and VAFs were
tested by using Wilcoxon rank sum tests. Overall quan-
tification of cfDNA (genome equivalents per milliliter of
plasma), median fragment length of cfDNA, PGA, z score,
MI, RB1 VAF, TP53 VAF, highest VAF all genes, and CTC
count at baseline number were compared by using
Spearman’s rho analysis. Associations of clinical vari-
ables (stage, sex, and performance status) and cfDNA
readouts were compared by using Fisher’s exact test.
Cancer Genome Interpreter
All somatic nonsynonymous variants detected across
the 62 cfDNA samples from patients with SCLC were fed
into an online platform, Cancer Genome Interpreter
(www.cancergenomeinterpreter.org),25 to interpret the
potential of variants detected in our study. This platform
also allows for identification of biomarkers of response
to anticancer drugs and the evidence that support the
same (Supplementary Tables 3–5).
Results
Evaluation of CNA Metrics and Sensitivity in
Control Samples
CNA data generated by low-pass, whole genome NGS
applied to a titration of PBMC/H446 nucleosomal DNAadmixtures are shown in Supplementary Figure 2A and B
and detailed in the Materials and Methods. In addition to
visualizing copy number gains and losses across the
genome (see Supplementary Fig. 2B), we generated and
compared three CNA numerical outputs: 1) Percent
genome amplified (PGA), 2) Z-score and 3) Moran's I,
reflecting different aspects of genome-wide changes
measurable in cfDNA: values reported were above the
thresholds set by using NCCs (see Supplementary Fig. 2A
and B). Percent genome amplified (PGA) sums the per-
centage of genome with a measurable copy number gain
as determined by HMMCopy26, Z-score is a previously
published cfDNAmetric27,28, and MI is a measure of spatial
autocorrelation often used to study stochastic processes
such as in geographical sciences29 that we evaluated as a
novel measure to gauge tumor content in cfDNA. A clear
decrease in copy number visualization was observed as
correlating with the proportion of H446 DNA present in
the titration samples with a decrease in numerical values
of each of the CNAmetrics (see Supplementary Fig. 2A and
B). PGA and Z-score measurements exceeded those of
NCCs in mixtures containing 10% H446 DNA. However,
the MI metric was more sensitive, identifying differences
relative to NCCs in mixtures containing 5% H446 DNA
(see Supplementary Fig. 2B).CNA Analysis of Patient Samples
We applied our approach to samples from 30 patients
with ES SCLC, 39 patients with LS SCLC, and 16 inde-
pendent samples from NCCs. The blood samples from all
69 patients (see Fig. 1B) were drawn at diagnosis
(before treatment). To increase the sensitivity of
genome-wide CNA detection, we exploited recent ob-
servations that ctDNA in the blood of patients with
cancer is slightly shorter than cfDNA from NCCs.30,31 To
establish whether the reduced ctDNA fragment length
seen with other solid cancers30,32 is also seen in SCLC,
we examined the median fragment length of all ES SCLC,
LS SCLC, and NCC cfDNA samples and showed that the
fragment size distribution in each group was statistically
distinct from that of the each of the others
(Supplementary Fig. 2C). Further, because selection of
NGS reads based on fragment size increased sensitivity
for both PGA and Z-score outputs (Supplementary
Table 6 and see also Supplementary Fig. 3), this size
selection strategy was applied in all subsequent CNA
analyses.
CNA readout (PGA, Z-score, and MI) thresholds were
set by using 16 cfDNA NCC samples (C1–C16) and
evaluated by applying them to an additional 16 test NCC
samples (C17–C32) and all 69 clinical samples
(Supplementary Table 7). The output from each of the
three CNA metrics for all samples (Fig. 2A and B and
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Figure 2. Copy number alterations (CNA) of patients with limited-stage (LS) SCLC, patients with extensive-stage (ES) SCLC,
and controls. (A) Copy number heatmap of circulating free DNA from 69 patients with SCLC. The top grouping includes all
patients with ES SCLC, the middle group includes all patients with LS SCLC, and the bottom group shows noncancer controls.
Each row represents a circulating free DNA analysis of a single patient. For the copy number heatmap, the x axis represents
each chromosome from chromosome 1 to chromosome 22 with regions in red indicating gains in copy number and regions in
blue indicating loss of copy number. For each sample, the values of the whole genome CNA metrics percent genome amplified
(PGA), Z-score (ZS), and Moran’s I (MI) are plotted as bar graphs to the right of the main heatmap. For each group, the patient
samples are arranged accordint to the descending value of PGA. (B) A comparison of the sensitivity of CNA metrics. The three
sets of Venn diagrams show the number of samples identified as positive for tumor DNA by using PGA,ZS, and MI values for all
patients, as well as for patients with ES SCLC and LS SCLC shown as separate groups. Chr, chromosome; ES, extensive-stage;
LS, limited-stage; PGA, Percent genome amplified; ZS, Z-score; MI, Moran's I.
February 2020 Profiling cfDNA in SCLC 221Supplementary Table 8) shows clear CNA detectable in
most of the SCLC cfDNA samples, whereas none of the 16
NCCs gave values above the predefined thresholds (see
Fig. 2A and B). A comparison of the three CNA readout
detection sensitivities revealed a high degree of overlap,
with MI showing the highest overall sensitivity and z
score showing the lowest (Supplementary Table 9 and
see also Fig. 2A and B and Supplementary Table 8). Using
CNA readouts, we detected tumor-related changes in
84% of all SCLC samples (58 of 69); 93% of the ES SCLC
samples (28 of 30), and 77% of the LS SCLC samples (30
of 39) (see Fig. 2B).
An examination of specific gains and losses iden-
tified in cfDNA revealed SCLC associated copy numberlosses (chromosomes 3p and 4) and gains (3q and 5p)
in 90% of patients with ES SCLC (27 of 30) and 74%
of patients with LS SCLC (29 of 39) (Supplementary
Tables 10 and 11 and see also Fig. 2B). Previously,
studies identified genes frequently lost or amplified in
SCLC,4,6,12 and these were confirmed in our cfDNA
CNA analysis. These SCLC-prevalent changes included
copy number gains for SOX2 (36 of 69 samples), MYC
(21 of 69 samples), NFIB (16 of 69 samples), and
CD274 molecule gene (CD274) (14 of 69 samples) and
copy number losses for contactin 3 gene (CNTN3) (41
of 69 samples), fragile histidine triad gene (FHIT) (40
of 69 samples), Ras association domain family mem-
ber 1 gene (RASSF1) (38 of 69 samples), RB1 (24 of 69
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Figure 3. Somatic mutations in SCLC circulating free DNA (cfDNA) and comparison of detection frequencies between cfDNA
and circulating tumor cell (CTC) readouts. (A) The 62 patient cfDNA samples (29 patients with ES SCLC and 33 patients with LS
SCLC) are arranged from left to right with each column representing mutation profile of an individual patient cfDNA sample.
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February 2020 Profiling cfDNA in SCLC 223samples), and kinesin heavy chain member 2A gene
(KIF2A) (20 of 69 samples) (see Supplementary
Tables 10 and 11). Statistically significant differ-
ences in CNA metrics were observed between ES SCLC
and LS SCLC (Supplementary Fig. 4A).
Targeted Sequencing of 110 Genes
Targeted sequencing of 110 SCLC-associated genes
(see Supplementary Table 1) was performed to detect
somatic nonsynonymous mutations present in cfDNA. Of
the 69 cfDNA samples analyzed for CNA, 62 (29 ES SCLC
and 33 LS SCLC samples) passed quality control for
targeted sequencing (see Supplementary Table 2). No
somatic nonsynonymous mutations were detected in any
of the 23 NCC samples tested. At least one non-
synonymous somatic mutation was detected in 94% of
the 62-patient cohort (Fig. 3A and B and see also
Supplementary Table 3): 97% of the 29 samples from
patients with ES SCLC and 91% of the 33 samples from
patients with LS SCLC. We detected TP53 mutations in
79% of the cohort (49 of 62): in 83% of the patients with
ES SCLC (24 of 29) and 76% of the patients with LS SCLC
(25 of 33) (Supplementary Tables 12 and 13 and see
also Supplementary Tables 3, 8 and 9 and Fig. 3A). We
also detected nonsynonymous somatic RB1 mutations in
34% of the patient samples (21 of 62), including those ofThe genes are arranged from top to bottom according to the inc
are displayed on the left y axis of the heatmap. The incidence
right y axis of the heatmap. (B) Detection frequencies were
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CREBBP, CREB binding protein gene; EP300, E1A binding protein
GNAS complex locus gene; KEAP1, kelch like ECH associated pro
mutS homolog 6 gene; MTOR, mechanistic target of rapamycin
NOTCH2, notch gene; NOTCH3, notch gene; PIK3CA, phosphati
gene; ALK, ALK receptor tyrosine kinase gene; APC, APC, WNT s
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sclerosis 1 gene; WT1, Wilms tumor 1 gene.38% of patients with ES SCLC (11 of 29) and 30% of
patients with LS SCLC (10 of 33) (see Supplementary
Tables 3, 12, and 13 and Fig. 3A).
Beyond TP53 and RB1, the most commonly mutated
genes were gene (COL22A1), lysine methyltransferase 2D
gene (KMT2D), notch 1 gene (NOTCH1), and mucin 16,
cell surface associated gene (MUC16) (see Fig. 3A and
Supplementary Tables 3, 12, and 13). An examination of
genes implicated in DDR (see Supplementary Table 1
[marked in red]) showed that 85% of patients (90% of
those with ES SCLC [26 of 29] and 82% of those with
LS SCLC [27 of 33]) had a mutation in at least one of
18 DDR genes (see Fig. 3A). Also, when the 23
RAS/phosphoinositide 3-kinase pathway genes (see
Supplementary Table 1 [marked in blue]) were exam-
ined, at least one somatic nonsynonymous mutation was
found in 32% of patients (38% of those with ES SCLC [11
of 29] and 27% of those with LS SCLC [9 of 33]) (see
Fig. 3A). In addition, 29% of patients with SCLC (38% of
those with ES SCLC [11 of 29] and 21% of those with LS
SCLC [seven of 33]) harbored at least one mutation in
the 28 genes involved in transcriptional regulation
(see Supplementary Table 1 [marked in green] and
Fig. 3A).
When the mutation profiles of LS SCLC and ES SCLC
were compared, there were no statistically significantidence of mutation of the gene in this cohort of patients and
of mutations occurring on a specific gene is annotated on the
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Figure 4. Potential clinical utility of circulating free DNA (cfDNA) readouts. (A) Kaplan-Meier curves of all 69 patients for (1)
disease stage, (2) z score, and (3) tumor protein p53 gene (TP53) variant allele fraction (VAF). (B) Copy number alteration
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224 Mohan et al Journal of Thoracic Oncology Vol. 15 No. 2differences in number of genes mutated or number of
mutations between the two groups (Supplementary
Fig. 3C). However, there were statistically significant
quantitative differences in VAF, with higher levels in ES
SCLC (p ¼ 0.0188 [see Supplementary Fig. 3C]), which is
consistent with the proportion of ctDNA present in total
cfDNA being higher in ES SCLC.Comparison of CNA, Targeted Mutation, and CTC
Detection
Of the 62 patient samples with both CNA and tar-
geted mutation data acquired, 58 (28 from patients with
ES SCLC and 30 from patients with LS SCLC) had at least
one somatic nonsynonymous mutation. For the single ES
SCLC sample in which no detectable somatic variants
Figure 5. Circulating free DNA copy number alteration (CNA) longitudinal analysis. Genome-wide CNA plots of three longi-
tudinal samples from six patients with SCLC: L18 (A), L19 (B), L21 (C), E20 (D), E30 (E), and E29 (F). For each patient there are
a baseline (BL) pretreatment sample and subsequent samples taken at end of treatment (eTx), samples taken at the follow-
up time point (before clinical detection of relapse) (FU), and samples taken at relapse (R). For each CNA plot, copy number
chromosomes (Chr) are indicated along the x axis, copy number and log-2 ratios are indicated along the y axis, gains are
indicated as red, and copy number losses are shown as blue.
February 2020 Profiling cfDNA in SCLC 225were detected (E7), we detected amplification of a TP53-
associated gene (tumor protein p53 regulating apoptosis
inducing protein 1 gene [TP53AIP1]), whereas for the
three LS SCLC samples with no detectable somatic vari-
ants (L3, L6, and L24), all CNA readouts were also
negative (see Fig. 3A and B). The overall coverage when
CNA and mutation detection were combined for all 62
eligible samples was 97% (60 of 62): 100% for the
samples from patients with ES SCLC (29 of 29) and 94%
of the samples from patients with for LS SCLC (31 of 33)
(see Fig. 3B).
CTC number (by CellSearch, EpCAM positive, pan-
cytokeratin positive, CD45 negative cells) is elevated in
SCLC compared with in other cancers and is prognostic
for OS.18 For the 62 patient samples subjected to both
CNA and targeted sequencing, we also obtained a CTC
count from a parallel blood sample taken at the same
time point as for the cfDNA analysis in 48 patients (28
with ES SCLC and 20 with LS SCLC). For these 48 pa-
tients, the mean and median CTC numbers per 7.5 mL of
blood were 523 and 5, respectively (range 0–15,352
[see Fig. 1B and Supplementary Fig. 3B), which is
consistent with the data from previous studies.18 For 37
of these 48 patients (24 of the 28 with ES SCLC and 13
of the 20 with LS SCLC), CellSearch detected at least one
CTC, whereas 46 of the same 48 patients (28 of the 28with ES SCLC and 18 of the 20 with LS SCLC) had
detectable ctDNA (see Fig. 3C and Supplementary
Table 8).
Readouts and Potential Clinical Utility
Correlation of cfDNA Readouts with Clinical
Outcomes. CNA metrics and VAFs differed significantly
between patients with ES SCLC and those with LS SCLC
(Supplementary Fig. 4A and C). Because CTC number (as
determined by CellSearch) is a prognostic biomarker for
OS in SCLC,18 we compared our cfDNA CNA readouts as
well as TP53 VAF and highest VAF with CTC number,
which showed a significant positive correlation (p 
0.0001 in all cases [Supplementary Tables 14 and 15 and
Supplementary Fig. 5A–C). In contrast, there was no
statistical correlation found between either the number
of genes mutated or the number of mutations present in
cfDNA with CTC counts (see Supplementary Fig. 5 and
Supplementary Tables 14 and 15). Similarly, there was
no statistical correlation found between any of the
cfDNA NGS–based readouts and cfDNA quantification
per milliliter of plasma (Supplementary Fig. 6 and see
also Supplementary Table 14).
Significant statistical associations were observed be-
tween clinical stage and cfDNA readouts (see
Supplementary Table 14). In univariate Cox regression
ETx RBL
Diagnosis DeathPartial Response
Progressed with
Brain Metastasis
)F
AV 35PT/
A
GP(
%
Days of Follow Up
cfDNA Samples0  40          160     240     320    400     480   560     640         760 ETxBL
0       40      80               160             240    280                       400
Diagnosis DeathPartial Response
Progressed in
Adrenals and Liver
)F
AV 35PT/
A
GP( 
%
Days of Follow Up
cfDNA SamplesR2FU1 FU2 R1
0
40
80
Diagnosis DeathPartial Response
Progressed in
Adrenals
%
 (P
G
A
/T
P5
3 
VA
F)
LB RxTE
0       40     80              160   200    240             320            400
Days of Follow Up
cfDNA Samples
0
20
30
10
Diagnosis
)F
AV 35PT/
A
GP( 
%
Progressed in
Adrenals and LiverPartial Response Death
RBL R2
Days of Follow Up
cfDNA Samples
0
20
30
10
0     40                   160  200  240          320  360  400  440
Diagnosis
)F
AV 35PT/
A
GP( 
%
Partial
Response Death
ETx RBL
Days of Follow Up
cfDNA Samples
0                  40                80                120                          180
0
40
80
Progressed 
with
Brain Metastasis
BL
Diagnosis DeathPartial Response
Progressed in
Nodes
%
 (P
G
A
/T
P5
3 
VA
F)
ETx
0
2
4
6
8
50
40
Days of Follow Up
cfDNA SamplesFU     0            40          80                                        200         240
0
20
30
10
C
B
A
F
E
D
TP53 VAF (%)
PGA (%)
1st Line Carboplatin/ Etoposide
2nd Line Carboplatin/ Etoposide
Radiotherapy
PCI
ETx
Figure 6. Patient time courses. Summary of the clinical course and blood biomarker readouts of six patients with SCLC: L18
(A), L19 (B), L21 (C), E20 (D), E30 (E), and E29 (F). In each plot, the x axis indicates the days of follow-up with the time point
corresponding to day 0 as diagnosis. The clinical events are indicated in blue along the top of each plot, the circulating free
DNA (cfDNA) samples are indicated along the x axis as baseline (BL), end of treatment (eTx), follow-up 1 (prerelapse clinic
appointment [FU1 or FU]), follow-up 2 (prerelapse clinic appointment [FU2]), and relapse (R). The treatment received and
the duration of treatment by the patient are indicated by the colored boxes on each plot, with yellow representing first-line
carboplatin/etoposide, blue for second-line carboplatin/etoposide, light green for prophylactic cranial irradiation (PCI), and
dark green for radiotherapy. Abbreviations: PGA, percent genome amplified; TP53, tumor protein p53 gene; VAF, variant
allele fraction.
226 Mohan et al Journal of Thoracic Oncology Vol. 15 No. 2analysis, the CNA readouts (p  0.001), TP53 VAF, and
highest VAF along with number of CTCs and lactate de-
hydrogenase (LDH) were identified as significant pre-
dictors of shorter survival (Supplementary Tables 16
and 17). The results of the univariate and multivariate
analyses of ctDNA-based scores in relation to each of the
clinical covariates in the cohorts (Fig. 4 A–C,
Supplementary Fig. 7A–D, and Supplementary
Tables 16 and 17) show significant relationship be-
tween stage of disease, z score, and number of mutations
per sample in multivariate analysis.Identification of Potential Actionable Mutations. To
establish whether the mutations detected by our
sequencing approach could have supported personalized
therapy, we evaluated all mutations by using the Cancer
Genome Interpreter (CGI25). Supplementary Table 3
presents findings for all 272 somatic nonsynonymous
mutations detected and the frequency of mutation across
all patients. As expected, many of the TP53 mutations
present in 78% of the samples were identified as cancer
driver mutations and some linked to potential therapies
(see Supplementary Tables 3–5). Excluding TP53
February 2020 Profiling cfDNA in SCLC 227mutations, CGI identified cancer drivers in 69% of
samples, with 60% linked to potential therapies (see
Fig. 4D and Supplementary Tables 3–5).
cfDNA Analysis for Disease Monitoring. To establish
whether the cfDNA approach we describe is suitable for
patient monitoring, longitudinal samples were available
from six patients (Supplementary Table 18 and Figs. 5
and 6 and see also Supplementary Table 5). In all six
patients there was detectable tumor-specific CNA
measurable at baseline, whereas at the end of treatment
no CNA was detected for four patients, a 10-fold CNA
reduction was seen for patient L19, and increased CNA
was seen for patient L21 (Fig. 5 A–F, Fig. 6A–F, and
Supplementary Table 18). CNA was detectable in four of
the five available relapse samples and in the follow-up
sample for patient L21 (see Fig. 5 B–F). For patient
L18 there was no detectable CNA in the relapse sample,
although there was disease progression with stable dis-
ease in lung and metastasis found in the brain (see
Figs. 5A and 6A).Discussion
We examined the levels and composition of ctDNA in
all stages of SCLC with a view to establishing a cfDNA
analysis pipeline suitable for routine patient monitoring
(see Fig. 1A). Whole genome CNA changes detectable in
cfDNA were obtained by using an optimized bioinfor-
matics workflow incorporating stringent elimination of
unreliable genomic regions and selective analysis of
shorter cfDNA fragments, thereby enriching for ctDNA33
(see Supplementary Fig. 3 and Supplementary Table 6).
Global CNA was measured by using three separate
readouts reflecting differing aspects of genomic change.
Given that the pattern and extent of CNA differ from
patient to patient, we reasoned that there may be dif-
ferences in the CNA readouts reflecting the varying na-
ture of each SCLC tumor. This prediction was borne out
by the finding that 54 of 69 patient samples were ctDNA
positive for all three readouts, one sample was detected
by PGA and MI, one sample was detected by PGA alone,
and one was detected by z score alone (see Fig. 2B).
Examination of the two PGA-positive, Z-score–negative
samples revealed small focal copy number gains
restricted to 0.24% and 2.02% of the genome (see Fig. 2
and Supplementary Table 8), which were insufficient to
register by using the genome-wide Z-score, demon-
strating that combining the three readouts increases
sensitivity by broadening the tumor-specific features
measured. MI has the additional benefit that it is calcu-
lated on the basis of tumor-associated alterations in an
individual cfDNA sample and it does not require the
support of control or germline samples for itscalculation. When all three CNA readouts (PGA, Z-score,
and MI) were used, tumor-related CNA changes were
seen in 84% of 69 patients with SCLC (93% of those with
ES SCLC and 77% of those with LS SCLC [see Fig. 2A and
B]). Similar CNA patterns were seen in the cfDNA sam-
ples in this study (see Fig. 2A and B and Supplementary
Tables 10 and 11), as previously reported for SCLC tu-
mors or SCLC CTCs.4,6,8,12,15
Recently, a panel of 430 genes has been applied to
ctDNA of patients with SCLC and an association of pre-
treatment ctDNA VAFs was linked to OS.22 Here we show
that each of the CNA readouts was also significantly
associated with OS (see Supplementary Table 15), and
Kaplan-Meier analysis suggested prognostic utility
similar to that with CellSearch CTC enumeration18 (see
Fig. 4A). Given the increased patient coverage of the
cfDNA readouts for patients with LS and ES compared
with CTC detection (see Figs. 3C and 4B), the simple CNA
readouts described here provide a valuable means for
prognosis and monitoring. It is important to point out
that the approach taken by us to identify CNA patterns in
pretreatment CTCs linked to treatment response8 cannot
currently be applied to our cfDNA analysis because of
varying dilution of ctDNA in cfDNA samples. However,
targeted NGS of a single cfDNA sample has the advantage
of providing a much simpler means of following specific
mutations compared with the analysis of multiple CTCs.8
In summary, the analysis of CTCs and cfDNA provide
differing yet overlapping information, and the aim of any
given study will determine whether it is sufficient to
analyze CTCs or cfDNA alone or whether both are
required.
Our CNA results are in agreement with those of
multiple studies demonstrating the effectiveness of CNA
readouts applied to many types of cancer,17,27,34 but to
our knowledge, this is the first CNA study analyzing a
cohort of more than 60 patients with SCLC, and the re-
sults demonstrate that the approach developed by us
will detect ctDNA at both early and late stages of SCLC.
Although there are no comparable studies of SCLC cfDNA
CNA, the higher sensitivities reached by using the com-
bined CNA readouts (79%–93% depending on stage of
disease) compare favorably with those reported with
targeted NGS applied to SCLC cfDNA, which have been
reported as 49% (n ¼ 51),7 85% (n ¼ 40),20 92.5%
(n ¼ 227),35 100% (n ¼ 22),22 and 100% (n ¼ 3).21
In addition, our CNA approach also led to the identifi-
cation of a focal amplification of the TP53-regulated
proapoptotic gene TP53AIP1 in SCLC (see Supplementary
Table 10). Because increased expression of TP53AIP1 has
been linked to poor prognosis in NSCLC36 but has not
been previously reported in SCLC, our findings suggest
that further investigation of TP53AIP1 in SCLC is
warranted.
228 Mohan et al Journal of Thoracic Oncology Vol. 15 No. 2Targeted sequencing of cfDNA is increasingly being
used to personalize treatment and monitor tumor
evolution and therapy-emergent resistance. Here we
show that after CNA analysis, the same whole genome
libraries can be used to identify at least one somatic
mutation in 93% of all SCLC samples (96% ES SCLC
and 90% LS SCLC), which is equivalent to the detection
rates previously reported for targeted sequencing of
SCLC cfDNA.7,20-22,35 As expected, we detected frequent
mutations in TP53 and RB1 and also saw a high fre-
quency of the COL22A1, KMT2D, NOTCH1, and MUC16
genes. We also show that we could pick up at least one
mutation in genes implicated in DDR in the cfDNA of
85% of patients with SCLC (90% of those with ES SCLC
and 82% of those with LS SCLC [see Supplementary
Table 3]), which may indicate selection for impaired
DDR in SCLC, which is a hypothesis that we will eval-
uate in a larger study now under way. Furthermore,
analysis of the cfDNA mutations in this study by using
CGI identified cancer drivers in 69% of samples, with
60% linked to potential therapies, indicating that this
targeted sequencing approach could support stratifi-
cation of patients with SCLC in future clinical trials (see
Supplementary Tables 3–5).
For a subgroup of six patients, we show that our
cfDNA CNA approach also provides an effective means
of disease monitoring in SCLC and that additional tar-
geted sequencing of our 110-gene panel provides a
potential means of patient stratification (see Figs. 5 and
6).11 For two patients (L21 and E20), detection of
ctDNA using either CNA or targeted sequencing pre-
ceded radiological progression (Figs. 5C and D and 6C
and D). For patient E20, mutational analysis identified
the presence of the TP53 mutation found in the pre-
treatment sample 14.6 weeks before radiological pro-
gression (see Figs. 5C and D and 6 C and D). Taken
together, these initial data suggest that our cfDNA CNA
approach combined with highly targeted sequencing of
TP53 will provide an effective means of monitoring of
patients with SCLC and can guide selection of suitable
samples for more extensive sequencing. Currently, ef-
forts are ongoing to address the potential of disease
monitoring by using cfDNA analyses in a larger cohort
of samples.
In summary, as the molecular segmentation of SCLC
disease emerges37 and rational drug development pro-
grams are now reaching early clinical testing,38 it is
essential that a clinically implementable strategy for
routine SCLC disease monitoring be established. The
liquid biopsy approaches that we have reported here
have been shown to provide effective baseline analysis
and longitudinal monitoring of both LS and ES diseaseand are now being incorporated into extended SCLC
studies and trials.
Acknowledgments
Funding for this study was from Cancer Research UK
(CRUK) through the core CRUK Manchester Institute
grant (C5759/A27412), the CRUK Manchester Centre
(C5759/A25254), the CRUK Lung Cancer Center of
Excellence (A25146), and the CRUK Manchester Exper-
imental Cancer Medicines Centre (A20465). Dr. Mohan’s
salary and consumable costs were funded through a
translational research grant to Dr. Dive (10001080/
AgrID486). Sample collection was undertaken via the
CONVERT trial (Concurrent Once-Daily versus Twice-
Daily RadioTherapy), and the ChemoRes trial (Molecu-
lar Mechanisms Underlying Chemotherapy Resistance,
Therapeutic Escape, Efficacy, and Toxicity–Improving
Knowledge of Treatment Resistance in Patients with
Lung Cancer). This work was supported by the National
Institute for Health Research (NIHR) Manchester
Biomedical Research Centre (BRC), and the NIHR
Christie Clinical Research Facility, and the Manchester
Medical Research Council (MRC) Single Cell Research
Centre (MR/M008908/1). The views expressed are
those of the author(s) and not necessarily those of the
National Health Service, the NIHR or the Department of
Health. We sincerely thank the patients and their fam-
ilies for provision of blood samples for research. Drs.
Brady, Dive, Blackhall, and Carr designed the study. Drs.
Blackhall, Faivre-Finn, Mr. Carter, and Ms. Priest
recruited and obtained consent from the patients,
collected blood samples, and provided clinical data. Drs.
Mohan, Rothwell, Brady, and Dive conceived and
designed the experiments. Drs. Mohan, Ayub, and Mr.
Smith performed the experiments. Drs. Mohan, Brady,
Leong, Sahoo, Schofield, Mr. Kilerci, Drs. Miller, and
Blackhall analyzed the data. Drs. Descamps and Zhou
performed the statistical analysis. Drs. Mohan, Brady,
Dive, and Blackhall interpreted the data. Drs. Mohan,
Brady, Leong, Foy and Dive prepared the article. All data
are available in the main text or the supplementary
materials. Genome data has been deposited at the Eu-
ropean Genome-Phenome Archive, which is hosted at the
European Bioinformatics Institute (EBI) and the Centre
for Genomic Regulation (CRG), under accession number
EGAS00001003110.
Supplementary Data
Note: To access the supplementary material accompa-
nying this article, visit the online version of the Journal of
Thoracic Oncology at www.jto.org and at https://doi.
org/10.1016/j.jtho.2019.10.007.
February 2020 Profiling cfDNA in SCLC 229References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J,
Jemal A. Global cancer statistics, 2012. CA Cancer J
Clin. 2015;65:87–108.
2. van Meerbeeck JP, Fennell DA, De Ruysscher DKM. Small-
cell lung cancer. Lancet. 2011;378:1741–1755.
3. Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent
once-daily versus twice-daily chemoradiotherapy in pa-
tients with limited-stage small-cell lung cancer
(CONVERT): an open-label, phase 3, randomised, supe-
riority trial. Lancet Oncol. 2017;18:1116–1125.
4. George J, Lim JS, Jang SJ, et al. Comprehensive
genomic profiles of small cell lung cancer. Nature.
2015;524:47–53.
5. Rudin CM. Genomic and epigenomic targets in small cell
lung cancer [abstract]. Clin Cancer Res. 2014;20(suppl
2):IA03.
6. Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive
genomic analysis identifies SOX2 as a frequently ampli-
fied gene in small-cell lung cancer. Nat Genet.
2012;44:1111–1116.
7. Fernandez-Cuesta L, Perdomo S, Avogbe PH, et al.
Identification of circulating tumor DNA for the early
detection of small-cell lung cancer. EBioMedicine.
2016;10:117–123.
8. Carter L, Rothwell DG, Mesquita B, et al. Molecular
analysis of circulating tumor cells identifies distinct
copy-number profiles in patients with chemosensitive
and chemorefractory small-cell lung cancer. Nat Med.
2016;23:114–119.
9. Booton R, Blackhall F, Kerr K. Individualised treatment in
non-small cell lung cancer: precise tissue diagnosis for
all? Thorax. 2011;66:273–275.
10. Rudin CM, Pietanza MC, Bauer TM, et al. Rovalpituzumab
tesirine, a DLL3-targeted antibody-drug conjugate, in
recurrent small-cell lung cancer: a first-in-human, first-
in-class, open-label, phase 1 study. Lancet Oncol.
2017;18:42–51.
11. Sen T, Gay CM, Byers LA. Targeting DNA damage repair in
small cell lung cancer and the biomarker landscape.
Transl Lung Cancer Res. 2018;7:50–68.
12. George J, Saito M, Tsuta K, et al. Genomic amplification
of CD274 (PD-L1) in small-cell lung cancer. Clin Cancer
Res. 2017;23:1220–1226.
13. Horn L, et al. first-line atezolizumab plus chemotherapy
in extensive-stage small-cell lung cancer. N Engl J Med.
2018;379:2220–2229.
14. Babayan A, Pantel K. Advances in liquid biopsy ap-
proaches for early detection and monitoring of cancer.
Genome Med. 2018;10:21.
15. Hodgkinson CL, Morrow CJ, Li Y, et al. Tumorigenicity
and genetic profiling of circulating tumor cells in small-
cell lung cancer. Nat Med. 2014;20:897–903.
16. Rothwell DG, Avub M, Cook N, et al. Utility of ctDNA to
support patient selection for early phase clinical trials:
the TARGET study. Nat Med. 2019;25:7387–43.
17. Mohan S, Heitzer E, Ulz P, et al. Changes in colorectal
carcinoma genomes under anti-EGFR therapy identifiedby whole-genome plasma DNA sequencing. PLoS Genet.
2014;10, e1004271.
18. Hou JM, Krebs MG, Lancashire L, et al. Clinical signifi-
cance and molecular characteristics of circulating tumor
cells and circulating tumor microemboli in patients with
small-cell lung cancer. J Clin Oncol. 2012;30:525–532.
19. Belic J, Graf R, Bauernhofer T, et al. Genomic alterations
in plasma DNA from patients with metastasized prostate
cancer receiving abiraterone or enzalutamide. Int J
Cancer. 2018;143:1236–1248.
20. Almodovar K, Iams WT, Meador CB, et al. Longitudinal
cell-free DNA analysis in patients with small cell lung
cancer reveals dynamic insights into treatment efficacy
and disease relapse. J Thorac Oncol. 2018;13:112–123.
21. Chaudhuri AA, Lovejoy AF, Chabon JJ, et al. Circulating
tumor DNA analysis during radiation therapy for local-
ized lung cancer predicts treatment outcome. Int J
Radiat Oncol Biol Phys. 2017;99:S1–S2.
22. Nong J, Gong Y, Guan Y, et al. Circulating tumor DNA
analysis depicts subclonal architecture and genomic
evolution of small cell lung cancer. Nat Commun.
2018;9:3114.
23. Board RE, et al. Isolation and extraction of circulating
tumor DNA from patients with small cell lung cancer. Ann
N Y Acad Sci. 2008;1137:98–107.
24. Li BT, Janku F, Jung B, et al. Ultra-deep next-generation
sequencing of plasma cell-free DNA in patients with
advanced lung cancers: results from the Actionable
Genome Consortium. Ann Oncol. 2019;30:597–603.
25. Tamborero D, Rubio-Perez C, Deu-Pons J, et al. Cancer
Genome Interpreter annotates the biological and clinical
relevance of tumor alterations. Genome Med.
2018;10:25.
26. Chan KC, Jiang P, Zheng YW, et al. Cancer genome
scanning in plasma: detection of tumor-associated copy
number aberrations, single-nucleotide variants, and tu-
moral heterogeneity by massively parallel sequencing.
Clin Chem. 2013;59:211–224.
27. Heitzer E, Ulz P, Belic J, et al. Tumor-associated copy
number changes in the circulation of patients with
prostate cancer identified through whole-genome
sequencing. Genome Med. 2013;5:30.
28. Chiu RW, Chan KC, Gao Y, et al. Noninvasive prenatal
diagnosis of fetal chromosomal aneuploidy by massively
parallel genomic sequencing of DNA in maternal plasma.
Proc Natl Acad Sci U S A. 2008;105:20458–20463.
29. Moran P. Notes on continuous stochastic phenomena.
Biometrika. 1950;37:17–23.
30. Jiang P, Chan CW, Chan KC, et al. Lengthening and
shortening of plasma DNA in hepatocellular carcinoma
patients. Proc Natl Acad Sci U S A. 2015;112:E1317–
E1325.
31. Mouliere F, Chandrananda D, Piskorz AM, et al. Enhanced
detection of circulating tumor DNA by fragment size
analysis. Sci Transl Med. 2018;10:eaat4921.
32. Giacona MB, Ruben GC, Iczkowski KA, Roos TB,
Porter DM, Sorenson GD. Cell-free DNA in human blood
plasma: length measurements in patients with
230 Mohan et al Journal of Thoracic Oncology Vol. 15 No. 2pancreatic cancer and healthy controls. Pancreas.
1998;17:89–97.
33. Scheinin I, Sie D, Bengtsson H, et al. DNA copy number
analysis of fresh and formalin-fixed specimens by shallow
whole-genome sequencing with identification and
exclusion of problematic regions in the genome assem-
bly. Genome Res. 2014;24:2022–2032.
34. Bardelli A, Corso S, Bertotti A, et al. Amplification of the
MET receptor drives resistance to anti-EGFR therapies in
colorectal cancer. Cancer Discov. 2013;3:658.
35. Morgensztern D, Dewvarakonda S, Masood A, et al. P1.
07-035. Circulating cell-free tumor DNA (cfDNA) testingin small cell lung cancer [abstract]. J Thorac Oncol.
2017;12:S717–S718.
36. Yamashita SI, Masuda Y, Yoshida N, et al.
p53AIP1 expression can be a prognostic marker
in non-small cell lung cancer. Clin Oncol.
2008;20:148–151.
37. Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer:
what we know, what we need to know and the path
forward. Nat Rev Cancer. 2017;17:725–737.
38. Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM.
Unravelling the biology of SCLC: implications for ther-
apy. Nat Rev Clin Oncol. 2017;14:549.
